Loading clinical trials...
Loading clinical trials...
Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients - REMAIN Study
Conditions
Interventions
Osimertinib
Locations
25
Italy
IRCCS Oncologico Giovanni Paolo II
Bari, BA, Italy
Asst Papa Giovanni Xxiii Sc Oncologia
Bergamo, BG, Italy
UOC di Oncologia Medica IRCCS - Policlinico S. Orsola Malpighi
Bologna, BO, Italy
Humanitas Istituto Clinico Catanese Contrada Cubba
Misterbianco, CT, Italy
A.S.S.T - Monza Ospedale San Gerardo
Monza, MB, Italy
Grande Ospedale Metropolitano Niguarda Ca' Granda
Milan, Michigan, Italy
Start Date
April 14, 2026
Primary Completion Date
December 1, 2028
Completion Date
December 1, 2028
Last Updated
April 22, 2026
Lead Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions